Loading clinical trials...
Loading clinical trials...
Disitamab Vedotin Combined With Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive Metastatic Gastric Cancer: A Prospective Phase Ib/II Study
Conditions
Interventions
Disitamab Vedotin combined with fruquintinib and Tislelizumab
Locations
1
China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Start Date
May 9, 2023
Primary Completion Date
May 1, 2025
Completion Date
December 1, 2025
Last Updated
August 9, 2023
NCT06532006
NCT05689463
NCT06488950
NCT05098197
NCT06230471
NCT06671613
Lead Sponsor
Fudan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions